Page 2 - Mike Erman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) -Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects ahead of a $5.75 billion bond issuance, three sources familiar with the situation said on Wednesday. The bad news prompted some bond investors to question whether Bayer should sweeten the terms of the deal or outright pull it, one of the sources said. The drug-to-pesticides group priced the investment grade bond on Thursday last week, with the deal closing on Tuesday.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer’s disease.

By Julie Steenhuysen

By Julie Steenhuysen CHICAGO (Reuters) - People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-...